ISRCTN10768387
Active, not recruiting
未知
Clinical demonstration for three-level prevention intervention of birth defect on monogenic disease (deafness)
Chinese PLA General Hospital0 sites10,000 target enrollmentJune 16, 2020
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Genetic deafness
- Sponsor
- Chinese PLA General Hospital
- Enrollment
- 10000
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Congenital hearing loss or late\-onset hearing loss and their families
- •2\. Patients with congenital malformation of auditory organ and their families
- •3\. Acquired sensorineural hearing loss patients and their families
- •4\. Hearing normal individuals with a family history of deafness
Exclusion Criteria
- •1\. The patients and their families who refused to participate in the program after receiving the education by doctors
- •2\. The patients with deafness caused by non\-genetic factors were definitely diagnosed
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Research on Three-level Prevention and Intervention for Elderly Depression in Urban CommunityDepression in Old AgeNCT06132061Affiliated Hospital of Yunnan University327
Active, not recruiting
Not Applicable
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - N/Ahigh-risk diffuse large B-cell lymphoma (DLBCL )EUCTR2005-004630-41-DEEli Lilly and Company limited709
Active, not recruiting
Not Applicable
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - PRELUDEHigh-risk diffuse large B-cell lymphoma (DLBCL)EUCTR2005-004630-41-GREli Lilly and Company Limited459
Active, not recruiting
Not Applicable
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - Preludehigh-risk diffuse large B-cell lymphoma (DLBCL )EUCTR2005-004630-41-DKEli Lilly and Company limited709
Active, not recruiting
Phase 1
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - N/Ahigh-risk diffuse large B-cell lymphoma (DLBCL )MedDRA version: 14.1Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2005-004630-41-CZEli Lilly and Company Limited709